2018 |
12/03 | 1,120 | 1,125 | 1,091 | 1,104 | -1.43% | 150,600 | 462億3696万 | -3.33% |
11/30 | 1,133 | 1,150 | 1,100 | 1,120 | -2.18% | 117,500 | 469億706万 | -1.67% |
11/29 | 1,149 | 1,156 | 1,132 | 1,145 | +1.42% | 115,600 | 479億5409万 | +0.88% |
11/28 | 1,140 | 1,147 | 1,123 | 1,129 | -1.74% | 92,300 | 472億8399万 | -0.62% |
11/27 | 1,133 | 1,157 | 1,119 | 1,149 | +4.08% | 149,600 | 481億2162万 | +1.14% |
11/26 | 1,098 | 1,109 | 1,077 | 1,104 | +2.32% | 83,200 | 462億3696万 | -2.99% |
11/22 | 1,064 | 1,095 | 1,046 | 1,079 | +2.08% | 114,300 | 451億8992万 | -5.52% |
11/21 | 15:30 TOKYO MX(東京メトロポリタンテレビジョン)「ザ・ビジョナリー~異才の花押~」当社社長兼CEO岩城裕一の出演のお知らせ |
11/21 | 1,055 | 1,079 | 1,046 | 1,057 | -3.12% | 162,100 | 442億6854万 | -8.01% |
11/20 | 1,100 | 1,110 | 1,089 | 1,091 | -2.33% | 90,400 | 456億9006万 | -5.79% |
11/19 | 1,075 | 1,137 | 1,072 | 1,117 | +0.27% | 167,000 | 467億7892万 | -4.2% |
11/16 | 1,136 | 1,149 | 1,100 | 1,114 | -2.02% | 87,900 | 466億5328万 | -4.95% |
11/15 | 1,085 | 1,145 | 1,082 | 1,137 | 0% | 139,900 | 476億1650万 | -3.48% |
11/14 | 1,158 | 1,180 | 1,131 | 1,137 | +0.71% | 156,400 | 476億1650万 | -3.73% |
11/13 | 1,051 | 1,175 | 1,051 | 1,129 | +2.54% | 274,500 | 472億8147万 | -4.97% |
11/12 | 1,153 | 1,169 | 1,097 | 1,101 | -8.02% | 344,100 | 461億885万 | -8.1% |
11/09 | 1,210 | 1,233 | 1,180 | 1,197 | -4.01% | 359,500 | 501億2925万 | -1.16% |
11/08 | 1,350 | 1,355 | 1,235 | 1,247 | -6.45% | 601,700 | 522億2320万 | +2.3% |
11/07 | 1,315 | 1,377 | 1,309 | 1,333 | +2.62% | 371,500 | 558億2480万 | +8.82% |
11/06 | 1,210 | 1,300 | 1,210 | 1,299 | +7.71% | 247,600 | 544億91万 | +5.61% |
11/05 | 1,198 | 1,235 | 1,196 | 1,206 | +0.75% | 115,100 | 505億616万 | -2.51% |
11/02 | 1,205 | 1,221 | 1,180 | 1,197 | +1.01% | 188,400 | 501億2925万 | -3.86% |
11/01 | 1,100 | 1,224 | 1,073 | 1,185 | +7.73% | 167,500 | 496億2670万 | -5.28% |
10/31 | 1,079 | 1,115 | 1,061 | 1,100 | +6.18% | 200,600 | 460億6698万 | -12.7% |
10/30 | 990 | 1,068 | 983 | 1,036 | +1.07% | 230,400 | 433億8671万 | -18.3% |
10/29 | 1,050 | 1,070 | 1,005 | 1,025 | -1.54% | 142,600 | 429億2604万 | -19.92% |
10/26 | 1,050 | 1,068 | 991 | 1,041 | +2.26% | 249,500 | 435億9611万 | -19.36% |
10/26 | 8:30 2018年12月期第3四半期決算短信〔米国基準〕(連結) |
10/25 | 1,049 | 1,085 | 1,009 | 1,018 | -12.92% | 504,600 | 426億3289万 | -21.63% |
10/24 | 1,145 | 1,173 | 1,102 | 1,169 | +2.54% | 225,900 | 489億5663万 | -10.7% |
10/23 | 1,185 | 1,205 | 1,139 | 1,140 | -4.52% | 205,800 | 477億4214万 | -13.18% |
10/22 | 1,181 | 1,206 | 1,155 | 1,194 | -1.49% | 238,500 | 500億361万 | -9.48% |
10/19 | 15:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ |
10/19 | 1,218 | 1,223 | 1,182 | 1,212 | -3.04% | 253,300 | 507億5743万 | -8.25% |
10/18 | 1,284 | 1,284 | 1,248 | 1,250 | -2.19% | 106,300 | 523億4884万 | -5.59% |
10/17 | 1,309 | 1,309 | 1,278 | 1,278 | -0.08% | 114,900 | 535億2145万 | -3.62% |
10/16 | 1,290 | 1,295 | 1,265 | 1,279 | -0.23% | 78,200 | 535億6333万 | -3.54% |
10/15 | 1,273 | 1,300 | 1,240 | 1,282 | +0.94% | 153,100 | 536億8897万 | -3.32% |
10/12 | 1,184 | 1,286 | 1,183 | 1,270 | +4.79% | 192,900 | 531億8642万 | -4.3% |
10/11 | 1,196 | 1,245 | 1,150 | 1,212 | -7.27% | 517,200 | 507億5743万 | -9.01% |
10/10 | 1,355 | 1,392 | 1,296 | 1,307 | -5.08% | 338,100 | 547億3594万 | -2.46% |
10/09 | 1,373 | 1,404 | 1,354 | 1,377 | -3.57% | 239,300 | 576億6748万 | +2.76% |
10/05 | 1,382 | 1,471 | 1,368 | 1,428 | +2.44% | 400,400 | 598億331万 | +6.73% |
10/05 | 8:00 MN-166のグリオブラストーマ(神経膠芽腫)治療適応に対するFDAのオーファンドラッグ指定のお知らせ |
10/04 | 1,400 | 1,418 | 1,388 | 1,394 | -0.57% | 123,400 | 583億7942万 | +4.58% |
10/04 | 8:00 BioJapan 2018にて登壇のお知らせ |
10/03 | 1,410 | 1,420 | 1,368 | 1,402 | -2.77% | 240,900 | 587億1446万 | +5.73% |
10/02 | 1,470 | 1,478 | 1,418 | 1,442 | -2.37% | 323,300 | 603億8962万 | +9.33% |
10/01 | 19:00 従業員株式購入プランの実施(新株発行)に関するお知らせ |
10/01 | 1,437 | 1,477 | 1,426 | 1,477 | +5.35% | 562,100 | 618億5539万 | +12.75% |
09/28 | 1,380 | 1,420 | 1,379 | 1,402 | +2.71% | 293,900 | 587億1446万 | +8.26% |
09/27 | 1,388 | 1,398 | 1,362 | 1,365 | -2.08% | 240,500 | 571億6493万 | +6.72% |
09/26 | 1,382 | 1,450 | 1,360 | 1,394 | +6.49% | 698,600 | 583億7942万 | +10.2% |
09/26 | 8:00 ALS(筋萎縮性側索硬化症)を適応とするMN-166のフェーズ3臨床試験に関するFDAからのポジティブなフィードバック受領のお知らせ |
09/25 | 1,300 | 1,311 | 1,287 | 1,309 | -1.06% | 151,800 | 548億1970万 | +4.8% |
09/21 | 1,349 | 1,358 | 1,302 | 1,323 | +0.23% | 210,700 | 554億601万 | +6.95% |
09/20 | 1,256 | 1,388 | 1,251 | 1,320 | +7.06% | 493,500 | 552億8037万 | +7.84% |
09/19 | 1,248 | 1,250 | 1,224 | 1,233 | -2.14% | 116,900 | 516億3689万 | +1.73% |
09/19 | 8:00 Ladenburg Thalmannの2018年ヘルスケア・カンファレンスへの参加のお知らせ |
09/18 | 1,275 | 1,279 | 1,250 | 1,260 | -1.25% | 90,400 | 527億6763万 | +4.48% |
09/14 | 1,280 | 1,304 | 1,268 | 1,276 | -0.93% | 86,000 | 534億3769万 | +6.6% |
09/13 | 1,230 | 1,291 | 1,225 | 1,288 | +3.54% | 97,800 | 539億4024万 | +8.33% |
09/12 | 1,266 | 1,277 | 1,213 | 1,244 | -2.81% | 177,900 | 520億9756万 | +5.33% |
09/11 | 1,305 | 1,310 | 1,280 | 1,280 | -2.51% | 140,100 | 536億521万 | +9.12% |
09/10 | 1,300 | 1,328 | 1,268 | 1,313 | +2.18% | 144,900 | 549億8722万 | +12.9% |
09/07 | 1,230 | 1,290 | 1,216 | 1,285 | +2.23% | 181,200 | 538億1460万 | +11.64% |
09/06 | 1,266 | 1,280 | 1,196 | 1,257 | -4.27% | 439,200 | 526億4199万 | +10.17% |
09/05 | 1,395 | 1,404 | 1,288 | 1,313 | -6.55% | 478,100 | 549億8722万 | +15.89% |
09/05 | 8:00 モルガン・スタンレー・グローバル・ヘルスケア・カンファレンス2018への参加のお知らせ |
09/04 | 1,382 | 1,420 | 1,374 | 1,405 | +0.72% | 294,500 | 588億4009万 | +25.11% |
09/03 | 1,398 | 1,406 | 1,351 | 1,395 | +4.89% | 459,800 | 584億2130万 | +25.9% |
08/31 | 1,291 | 1,330 | 1,291 | 1,330 | +0.3% | 284,200 | 556億9916万 | +21.46% |
08/30 | 1,329 | 1,350 | 1,311 | 1,326 | +3.43% | 478,900 | 555億3165万 | +22.32% |
08/30 | 8:00 MN-166の進行型多発性硬化症(SPRINT-MS)フェーズ2b臨床治験結果のNew England Journal of Medicineへの論文掲載のお知らせ |
08/29 | 1,248 | 1,290 | 1,235 | 1,282 | +3.81% | 381,000 | 536億8897万 | +19.26% |
08/28 | 1,250 | 1,262 | 1,227 | 1,235 | +0.16% | 290,500 | 517億2065万 | +15.96% |
08/27 | 1,225 | 1,250 | 1,208 | 1,233 | +2.84% | 416,600 | 516億3689万 | +16.76% |
08/24 | 1,120 | 1,220 | 1,120 | 1,199 | +8.02% | 448,800 | 502億1300万 | +14.74% |
08/23 | 1,005 | 1,290 | 1,001 | 1,110 | +9.9% | 1,412,400 | 464億8577万 | +7.14% |
08/22 | 1,008 | 1,019 | 992 | 1,010 | +1.61% | 83,500 | 422億9786万 | -2.04% |
08/22 | 8:00 臨床治験データの事後解析に関する東京理科大学との共同研究契約締結のお知らせ |
08/21 | 1,011 | 1,016 | 990 | 994 | -1.78% | 75,900 | 416億2779万 | -3.59% |
08/21 | 8:00 米国国立アルコール摂取障害・依存症研究所からのR01研究助成金授与のお知らせ~MN-166のアルコール摂取障害を対象とするフェーズ2b臨床治験~ |
08/20 | 990 | 1,013 | 977 | 1,012 | +2.22% | 75,300 | 423億8162万 | -1.75% |
08/17 | 980 | 1,000 | 978 | 990 | -1.2% | 161,300 | 414億6028万 | -3.88% |
08/16 | 1,031 | 1,031 | 987 | 1,002 | -3.65% | 153,100 | 419億6283万 | -2.62% |
08/15 | 1,065 | 1,073 | 1,037 | 1,040 | -2.16% | 106,500 | 435億5423万 | +1.17% |
08/14 | 1,040 | 1,074 | 1,038 | 1,063 | +2.41% | 77,500 | 445億1745万 | +3.2% |
08/13 | 1,055 | 1,060 | 1,035 | 1,038 | -4.33% | 146,200 | 434億7047万 | +1.37% |
08/10 | 1,087 | 1,097 | 1,069 | 1,085 | +0.46% | 115,400 | 454億3879万 | +6.58% |
08/09 | 1,042 | 1,083 | 1,042 | 1,080 | +4.25% | 199,900 | 452億2939万 | +7.57% |
08/08 | 1,047 | 1,051 | 1,021 | 1,036 | -0.38% | 97,900 | 433億8671万 | +4.44% |
08/07 | 1,023 | 1,090 | 1,014 | 1,040 | +3.48% | 167,100 | 435億5423万 | +5.69% |
08/07 | 8:00 MN-166のDegenerative Cervical Myelopathy(変性性頸椎脊椎症)を対象とするケンブリッジ大学とのフェーズ2⁄3共同臨床治験の開始のお知らせ |
08/06 | 1,031 | 1,038 | 997 | 1,005 | -4.74% | 134,600 | 420億8846万 | +2.97% |
08/03 | 1,059 | 1,069 | 1,038 | 1,055 | 0% | 55,600 | 441億8242万 | +8.65% |
08/02 | 1,060 | 1,065 | 1,036 | 1,055 | +0.86% | 89,500 | 441億8242万 | +9.55% |
08/01 | 1,021 | 1,062 | 1,021 | 1,046 | +0.58% | 60,100 | 438億551万 | +9.3% |
08/01 | 8:00 第29回ALS/MND国際シンポジウムにおけるMN-166のALSを適応とする臨床治験事後解析(ad-hoc)データの発表のお知らせ |
07/31 | 1,067 | 1,067 | 1,021 | 1,040 | -2.53% | 88,400 | 435億5423万 | +9.24% |
07/30 | 1,093 | 1,094 | 1,060 | 1,067 | +0.19% | 81,300 | 446億8497万 | +12.67% |
07/30 | 8:00 ALS(筋萎縮性側索硬化症)を適応とするMN-166の効果をバイオマーカーで評価する臨床治験の患者登録完了のお知らせ |
07/27 | 1,104 | 1,120 | 1,063 | 1,065 | -1.66% | 173,600 | 446億121万 | +13.18% |
07/26 | 1,066 | 1,096 | 1,055 | 1,083 | +4.54% | 221,900 | 453億5503万 | +15.71% |
07/25 | 1,020 | 1,075 | 1,006 | 1,036 | +2.07% | 207,900 | 433億8671万 | +11.4% |
07/24 | 10:00 2018年12月期第2四半期決算説明会資料 |
07/24 | 933 | 1,097 | 921 | 1,015 | +7.18% | 534,300 | 425億725万 | +9.85% |
07/24 | 8:30 2018年12月期第2四半期決算短信〔米国基準〕(連結) |
07/23 | 951 | 959 | 928 | 947 | -3.86% | 126,200 | 396億5948万 | +2.82% |
07/20 | 15:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ |
07/20 | 990 | 993 | 973 | 985 | -0.3% | 85,600 | 412億5088万 | +7.07% |
07/19 | 998 | 1,006 | 979 | 988 | -0.8% | 86,100 | 413億7652万 | +7.74% |
07/18 | 1,000 | 1,012 | 989 | 996 | +0.3% | 102,200 | 417億1155万 | +8.73% |
07/17 | 1,001 | 1,017 | 982 | 993 | -0.7% | 105,200 | 415億8591万 | +8.29% |
07/13 | 983 | 1,038 | 973 | 1,000 | +4.93% | 271,000 | 418億7907万 | +9.05% |
07/12 | 956 | 969 | 930 | 953 | -4.8% | 337,200 | 399億1075万 | +3.81% |
07/11 | 994 | 1,040 | 978 | 1,001 | -6.62% | 474,200 | 419億2095万 | +8.57% |
07/10 | 952 | 1,072 | 951 | 1,072 | +16.27% | 678,400 | 448億9436万 | +16.27% |
07/10 | 8:00 MN-166のALS(筋萎縮性側索硬化症)を適応とする臨床治験でのサブグループ解析データ発表のお知らせ |